A first-in-human phase I study of sEphB4-HSA in patients with advanced solid tumors with expansion at the maximum tolerated dose (MTD) or recommended phase II dose (RP2D)
El-Khoueiry, A., Gitlitz, B., Cole, S., Tsao-Wei, D., Goldkorn, A., Quinn, D., Lenz, H.J., Nieva, J., Dorff, T., Oswald, M., Berg, J., Menendez, X., Karakozian, K., Krasnoperov, V., Liu, R., Thomas, JVolume:
69
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/s0959-8049(16)32623-5
Date:
December, 2016
File:
PDF, 49 KB
english, 2016
File converter
More search results
More benefits 
